Aurinia Pharmaceuticals (AUPH)
(Real Time Quote from BATS)
$5.32 USD
+0.02 (0.38%)
Updated Jun 10, 2024 12:26 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Aurinia Pharmaceuticals Inc [AUPH]
Reports for Purchase
Showing records 101 - 120 ( 138 total )
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Dosing Protocol Patent for Voclosporin Is a Big Deal; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Exploratory Dry Eye Data Strongly Encouraging Despite Primary Miss; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
2019 TOP IDEAS-Healthcare Sector Review Preview.
Provider: Bloom Burton & Company
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Dry Eye Data in Late January; New CEO Likely in 2019 Ahead of Pivotal LN Data; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Enrollment in Pivotal AURORA Trial Complete; Surpassing Target; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
2Q Recap: Voclosporin Now in Three Active Clinical Programs; Raise PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Full Enrollment of AURORA by Year End; Initiation of FSGS and VOS Studies in 2Q18; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
2018 Top Ideas; Healthcare Sector Review/Preview
Provider: Bloom Burton & Company
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
3Q Recap: AURORA Marches On; New Programs in FSGS and Dry Eye to Start in 1H18; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
R-D Day Showcases New Indications, Expanded Opportunity; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Voclosporin Enters Confirmatory Phase 3; With Coffers Full, We Reduce PT to $10 on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Additional 48-Week Efficacy and Safety Data Validates Voclosporin in LN ; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
No Extra Hurdles for International Approval of Voclosporin
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Landmark Data Drives Increased Confidence in Phase 3 and Commercial Uptake; Raise PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Aurinia Founder and Chairman Takes Over as CEO; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
2017 Top Ideas; Healthcare Sector Review/Preview
Provider: Bloom Burton & Company